Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 6.


Back, David, Marzolini, Catia, Hodge, Catherine ORCID: 0000-0003-2288-7020, Marra, Fiona, Boyle, Alison, Gibbons, Sara, Burger, David and Khoo, Saye
(2020) COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY.


Marra, Fiona, zu Siederdissen, Christoph Hoener, Khoo, Saye, Back, David, Schlag, Michael, Ouwerkerk-Mahadevan, Sivi, Bicer, Ceyhun, Lonjon-Domanec, Isabelle, Jessner, Wolfgang, Beumont-Mauviel, Maria
et al (show 2 more authors) (2018) Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84 (5). 961 - 971.


Hodge, Catherine, Marra, Fiona, Marzolini, Catia, Boyle, Alison, Gibbons, Sara, Siccardi, Marco, Burger, David, Back, David and Khoo, Saye
(2020) Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. The Journal of antimicrobial chemotherapy, 75 (12). 3417 - 3424.


Back, David, Belperio, Pamela, Bondin, Mark, Negro, Francesco, Talal, Andrew H, Park, Caroline, Zhang, ZhenZhen, Pinsky, Brett, Crown, Eric, Mensa, Federico J
et al (show 1 more authors) (2019) Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. JOURNAL OF VIRAL HEPATITIS, 26 (8). 951 - 960.


Schulte, Benjamin, Wuebbolding, Maximilian, Marra, Fiona, Port, Kerstin, Manns, Michael P, Back, David, Cornberg, Markus, Stichtenoth, Dirk O, zu Siederdissen, Christoph Hoener and Maasoumy, Benjamin
(2020) Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. OPEN FORUM INFECTIOUS DISEASES, 7 (2).


Ferenci, Peter, Bourgeois, Stefan, Buggisch, Peter, Norris, Suzanne, Curescu, Manuela, Larrey, Dominique, Marra, Fiona, Kleine, Henning, Dorr, Patrick, Charafeddine, Mariem
et al (show 4 more authors) (2019) Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. JOURNAL OF VIRAL HEPATITIS, 26 (6). 685 - 696.

This list was generated on Sat Nov 21 09:25:31 2020 GMT.